Status:
COMPLETED
Health Literacy - Neurocognitive Screening in Pediatric SCD
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
6-17 years
Phase:
NA
Brief Summary
The purpose of this study is to determine feasibility and potential benefits of providing a passport card with a summary of neurocognitive feedback results to families of patients with sickle cell dis...
Detailed Description
Pediatric sickle cell disease (SCD) is a blood disorder affecting approximately 70,000 to 100,000 individuals in the United States. Approximately 80% of individuals affected by SCD are African America...
Eligibility Criteria
Inclusion
- Participants will include English-speaking patients between the ages of 6 and 17 with pediatric sickle cell disease and their caregivers (46 patient-caregiver dyads).
Exclusion
- Patients will be excluded from participation if they have a history of significant neurological injury or impairment negating the benefit of a neurocognitive screening
Key Trial Info
Start Date :
September 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 8 2021
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04917783
Start Date
September 25 2019
End Date
September 8 2021
Last Update
April 5 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Wisconsin
Milwaukee, Wisconsin, United States, 53201
2
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53266